Key result
Peripartum cardiomyopathy affects ~1% of deliveries in Northern Nigeria, marking the world's highest burden.
Why the study?
Comparative post-marketing safety data between nirsevimab and palivizumab in infants were limited.
Key points are not available for this paper at this time.
Population
2,021 reports of patients ≤2 years old
Comparison
Nirsevimab vs palivizumab
Design
Post-marketing adverse event report analysis using FAERS
Follow-up
July 2023 to March 2025
Answers are grounded in this paper and cite their sources.
Alerts clinicians to high northern Nigeria PPCM burden for targeted vigilance; leaves open need for prospective studies on etiology and care.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ogah et al. (2020) studied this question. Peripartum cardiomyopathy occurs in one out of every 100 deliveries in the western axis of Northern Nigeria, representing the highest burden of the condition worldwide.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: